Andreas Duma1, Daniel Helsten, Frank Brown, Michael M Bottros, Peter Nagele. 1. From the *Department of Anesthesiology, Washington University in St Louis, St Louis, MO; and †Department of Anesthesiology and General Intensive Care, Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND AND OBJECTIVES: Many patients experience moderate to severe postoperative pain. Nitrous oxide (N₂O) exerts analgesia by inhibition of N-methyl-D-aspartate receptors. Ketamine, another N-methyl-D-aspartate receptor antagonist, reduces postoperative opioid consumption and pain. A similar effect of N₂O is plausible, yet understudied. The goal of this study was to determine the effects of N₂O anesthesia on early postsurgical opioid consumption and pain. METHODS: This was a retrospective, secondary analysis of the Vitamins In Nitrous Oxide trial, where 500 patients undergoing general anesthesia for noncardiac surgery received 60% N₂O and 125 received no N₂O (otherwise, inclusion/exclusion criteria were identical). Exclusion criteria for this study were regional anesthesia, not extubated after surgery, transfer to intensive care unit, no available postanesthesia care unit record, postsurgical sedation, or treated withnaloxone. Primary outcomes were cumulative opioid consumption measured in morphine equivalents and pain scores during the immediate recovery phase. RESULTS:Four hundred forty-two patients met inclusion criteria. No difference in intraoperative and postoperative opioid consumption was observed between patients who received N₂O (n = 353) and patients who did not (n = 89). The median [interquartile range] postoperative morphine equivalent dose was 6.7 mg [1.7-14.1 mg] for patients who received N₂O and 6.7 mg [2.1-15.4 mg] for patients who did not (P = 0.73). The maximum pain score was 6 [4-8] for patients who received N₂O versus 6 [3-8] for patients who received N₂O-free anesthesia (P = 0.52). The prevalence of moderate to severe pain was 69% for patients who received N₂O and 68% for patients who did not (P = 0.90). CONCLUSIONS:Nitrous oxide anesthesia was not associated with decreased opioid administration, pain, or incidence of moderate to severe pain in the early postoperative phase.
RCT Entities:
BACKGROUND AND OBJECTIVES: Many patients experience moderate to severe postoperative pain. Nitrous oxide (N₂O) exerts analgesia by inhibition of N-methyl-D-aspartate receptors. Ketamine, another N-methyl-D-aspartate receptor antagonist, reduces postoperative opioid consumption and pain. A similar effect of N₂O is plausible, yet understudied. The goal of this study was to determine the effects of N₂O anesthesia on early postsurgical opioid consumption and pain. METHODS: This was a retrospective, secondary analysis of the Vitamins In Nitrous Oxide trial, where 500 patients undergoing general anesthesia for noncardiac surgery received 60% N₂O and 125 received no N₂O (otherwise, inclusion/exclusion criteria were identical). Exclusion criteria for this study were regional anesthesia, not extubated after surgery, transfer to intensive care unit, no available postanesthesia care unit record, postsurgical sedation, or treated with naloxone. Primary outcomes were cumulative opioid consumption measured in morphine equivalents and pain scores during the immediate recovery phase. RESULTS: Four hundred forty-two patients met inclusion criteria. No difference in intraoperative and postoperative opioid consumption was observed between patients who received N₂O (n = 353) and patients who did not (n = 89). The median [interquartile range] postoperative morphine equivalent dose was 6.7 mg [1.7-14.1 mg] for patients who received N₂O and 6.7 mg [2.1-15.4 mg] for patients who did not (P = 0.73). The maximum pain score was 6 [4-8] for patients who received N₂O versus 6 [3-8] for patients who received N₂O-free anesthesia (P = 0.52). The prevalence of moderate to severe pain was 69% for patients who received N₂O and 68% for patients who did not (P = 0.90). CONCLUSIONS:Nitrous oxide anesthesia was not associated with decreased opioid administration, pain, or incidence of moderate to severe pain in the early postoperative phase.
Authors: G Echevarría; F Elgueta; C Fierro; D Bugedo; G Faba; R Iñiguez-Cuadra; H R Muñoz; L I Cortínez Journal: Br J Anaesth Date: 2011-09-28 Impact factor: 9.166
Authors: Douglas S Ramsay; Brian G Leroux; Marilynn Rothen; Christopher W Prall; Louis O Fiset; Stephen C Woods Journal: Pain Date: 2005-03 Impact factor: 6.961
Authors: Randy W Loftus; Mark P Yeager; Jeffrey A Clark; Jeremiah R Brown; William A Abdu; Dilip K Sengupta; Michael L Beach Journal: Anesthesiology Date: 2010-09 Impact factor: 7.892
Authors: Francis Remérand; Charlotte Le Tendre; Annick Baud; Claude Couvret; Xavier Pourrat; Luc Favard; Marc Laffon; Jacques Fusciardi Journal: Anesth Analg Date: 2009-12 Impact factor: 5.108